Last reviewed · How we verify
ADH -1 and capecitabine
ADH-1 is a vasopressin receptor antagonist, and capecitabine is a thymidylate synthase inhibitor.
ADH-1 is a vasopressin receptor antagonist, and capecitabine is a thymidylate synthase inhibitor. Used for Breast cancer, Colorectal cancer.
At a glance
| Generic name | ADH -1 and capecitabine |
|---|---|
| Sponsor | Adherex Technologies, Inc. |
| Drug class | Vasopressin receptor antagonist, chemotherapy agent |
| Target | Vasopressin receptor, thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ADH-1 works by blocking the action of vasopressin, a hormone that causes water retention, while capecitabine is a chemotherapy medication that interferes with DNA synthesis in cancer cells.
Approved indications
- Breast cancer
- Colorectal cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADH -1 and capecitabine CI brief — competitive landscape report
- ADH -1 and capecitabine updates RSS · CI watch RSS
- Adherex Technologies, Inc. portfolio CI